RACE's newly appoint VP of Clinical, Dr Simon Fisher spoke to this point in terms of the expansion of clinical trial sites to South Korea and Hong Kong referring to 'partnering' in those geographical regions. See the Proactive video interview below from ~2.40 mark.
Pete Smith and Dr T have been telegraphing to shareholders for well over 18months a geographical license deal is a sensible pathway RACE is considering and China (Asia) being a logical region for an early deal.
Perhaps those partner/s are just awaiting those final boxes to be ticked: - RC220 safely administered - tick - RC220/Dox safely administered with no dose limiting toxicities - tick - What is the final box? Dosing at the first cohort level, rather than just first patient? Or are they satisfied with the drug's performance and it is now purely coming to commercial terms on such a deal? I'd say we'll find out in the next few weeks/months.
RAC Price at posting:
$1.29 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)